Comparison of leptin serum levels in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS)

Document Type : Original Article (s)

Authors

1 Professor of Pathology, Department of Pathology, School of Medicine, Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Department of Neurology, School of Medicine, Neurosciences Research Center Kashani Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

3 School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

10.48305/jims.v43.i821.0759

Abstract

Background: Given the increased levels of the hormone leptin in some autoimmune and inflammatory diseases, including multiple sclerosis (MS) as a chronic progressive disease, the present study was conducted to determine and compare the mean serum level of leptin in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS).
Methods: In this cross-sectional study conducted in 2021 at Kashani Hospital in Isfahan, 16 patients with RRMS and 16 patients with SPMS were selected according to the 2015 McDonald criteria. Leptin serum levels were evaluated in the two groups using a leptin kit from the LDN company and the ELISA method, and compared using the Chi-square and Mann-Whitney statistical tests.
Findings: The median leptin serum level in the RRMS and SPMS groups was 29.5 (15.5- 34.75), and 42 (35.25-46.75) respectively, and the difference between the scores of the two groups was significant (P = 0.003). Other findings showed no significant correlation between leptin serum levels and age, BMI, or EDSS.
Conclusion: Based on the results of the study, serum leptin levels in patients with multiple sclerosis could potentially be introduced as a biomarker and used for better diagnosis and follow-up of patients.

Highlights

Azar Baradaran: Google Scholar

Vahid Shaygannejad: Google Scholar

Keywords

Main Subjects

References

  1. Rodi M, Dimisianos N, De Lastic A-L, Sakellaraki P, Deraos G, Matsoukas J, et al. Regulatory cell populations in relapsing-remitting multiple sclerosis (RRMS) patients: effect of disease activity and treatment regimens. Int J Mol Sci 2016; 17(9): 1398.
  2. Matarese G, Carrieri PB, La Cava A, Perna F, Sanna V, De Rosa V, et al. Leptin increase in multiple sclerosis associates with reduced number of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci U S A 2005; 102(14): 5150-5.
  3. Babaei A, Zarkesh-Esfahani SH, Bahrami E, Ross RJ. Restricted leptin antagonism as a therapeutic approach to treatment of autoimmune diseases. Hormones (Athens) 2011; 10(1): 16-26.
  4. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372(6505): 425-32.
  5. Cava AL, Matarese G. The weight of leptin in immunity. Nat Rev Immunol 2004; 4(5): 371-9.
  6. Zarkesh-Esfahani H, Pockley AG, Wu Z, Hellewell PG, Weetman AP, Ross RJ. Leptin indirectly activates human neutrophils via induction of TNF-α. J Immunol 2004; 172(3): 1809-14.
  7. Matarese G, Carrieri PB, La Cava A, Perna F, Sanna V, De Rosa V, et al. Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. Proc Natl Acad Sci U S A 2005; 102(14): 5150-5.
  8. Frisullo G, Mirabella M, Angelucci F, Caggiula M, Morosetti R, Sancricca C, et al. The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis. J Neuroimmunol 2007; 192(1-2): 174-83.
  9. Emamgholipour S, Eshaghi SM, Hossein-nezhad A, Mirzaei K, Maghbooli Z, Sahraian MA. Adipocytokine profile, cytokine levels and foxp3 expression in multiple sclerosis: a possible link to susceptibility and clinical course of disease. PLoS One 2013; 8(10): e76555.
  10. Przybek J, Gniatkowska I, Mirowska-Guzel D, Członkowska A. Evolution of diagnostic criteria for multiple sclerosis. Neurol Neurochir Pol 2015; 49(5): 313-21.
  11. Messina S, Vargas-Lowy D, Musallam A, Healy BC, Kivisakk P, Gandhi R, et al. Increased leptin and A-FABP levels in relapsing and progressive forms of MS. BMC Neurol 2013; 13: 172.
  12. Fahmi RM, Kamel AE, Elsayed DA, Zidan AA, Sarhan NT. Serum levels of leptin and adiponectin in patients with multiple sclerosis. Egypt J Neurol Psychiatry Neurosurg 2021; 57: 114.
  13. Komori M, Matsuyama Y, Nirasawa T, Thiele H, Becker M, Alexandrov T, et al. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders. Ann Neurol 2012; 71(5): 614-23.
Journal of Isfahan Medical School
Volume 43, Issue 821
1st Week, September
September and October 2025
Pages 759-763

Files

History

  • Receive Date: 10 June 2025
  • Accept Date: 11 August 2025

Share

How to cite

Statistics